Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer treated with modern chemotherapy (FLOT): Experience in patients in Guatemala.
Authors
Rixci Ramirez
Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala
Rixci Ramirez , Daniel Estuardo Rosales-Lopez , Jennifer Dominguez , Carolina Camey , Julia Ovalle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 287)
DOI
10.1200/JCO.2024.42.3_suppl.287
Abstract #
287
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with docetaxel plus oxaliplatin and S-1 for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma: Short-term results from a phase II trial.
First Author: Tomono Kawase
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.
First Author: James Tankel
Poster
2021 Gastrointestinal Cancers Symposium
Gastric and gastroesophageal adenocarcinoma survival outcomes relative to completion of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A single-center retrospective analysis.
First Author: Michael J Allen